<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95678">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01777256</url>
  </required_header>
  <id_info>
    <org_study_id>115919</org_study_id>
    <nct_id>NCT01777256</nct_id>
  </id_info>
  <brief_title>An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184</brief_title>
  <official_title>An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Estonia: State Agency of Medicines</authority>
    <authority>Argentina: National Administration of Medicines, Food and Medical Technology</authority>
    <authority>Peru: National Institute of Health</authority>
    <authority>Romania: National Agency for Drug and Medical Devices</authority>
    <authority>Chile: Public Health Institute</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Korea: Korea Food and Drug Administration [KFDA]</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: National Agency for the Safety of Medicine and Health Products</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Greece: National Organization for Medicines</authority>
    <authority>Spain: Spanish Agency for Medicines and Health Products</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an adaptive, dose ranging, Phase II study to investigate the relationship between
      repeat doses of GSK2586184 and the pharmacodynamic effect and clinical efficacy in patients
      with active systemic lupus erythematosus (SLE). This study will also investigate the safety
      and tolerability of repeat doses of GSK2586184. During the study, up to 3 Interim Analyses
      will be conducted. These are to monitor the pharmacodynamic effect and safety following 2
      weeks of therapy (Interim Analysis 1); and the clinical efficacy and safety of GSK2586184
      following 12 weeks of therapy (Interim Analyses 2 and 3). Subjects who meet the entry
      criteria (approximately 150 to 250) will be randomized in a 1:1:1:1:1 ratio to receive
      GSK2586184 at doses of 50 milligram (mg) twice daily (b.i.d), 100 mg b.i.d, 200 mg b.i.d,
      400 mg b.i.d or Placebo b.i.d. GSK2586184 tablets available in 50 and 200 mg dose strength
      will be administered orally up to 12 weeks.

      Subjects who complete the study will participate in the study for approximately 21 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study met a protocol defined futility criterion and will be terminated following
    completion of the Follow Up Visit on the last subject randomised.
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Interferon biomarkers over time</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The relationship between dose of GSK2586184 and pharmacodynamic effect on expression of selected mRNA transcripts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SELENA SLEDAI score over time</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Safety of Estrogen in Lupus National Assessment (SELENA) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) is a validated index for assessing SLE disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline for vital signs</measure>
    <time_frame>Baseline and up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vital sign measurements will include heart rate, sitting blood pressure, and temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical chemistry and hematology parameters</measure>
    <time_frame>Baseline and up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical laboratory tests will include hematology, clinical chemistry and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events and severity of adverse events</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adverse events (AEs) will be collected from the start of Investigation Product and until the follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SRI Response Rate over time</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The relationship between dose of GSK2586184 and clinical response will be assessed by the SLE Responder Index (SRI). Response is defined as:&gt;= 4 point reduction from baseline in the SELENA SLEDAI score and no worsening (increase of &lt;0.30 points from baseline) in Physicians Global Assessment (PGA),and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SLEDAI-2K score and the S2K RI-50 score</measure>
    <time_frame>Baseline and Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The relationship between dose of GSK2586184 and clinical response will be assessed by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and SLEDAI-2K Responder Index 50 (S2K RI-50) scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual and summary PK parameters</measure>
    <time_frame>Weeks 2, 4, 8, 10 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic (PK) parameters for GSK2586184 will be measured to evaluate PK of repeat doses of GSK2586184.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Short Form-36 Health Survey (SF-36) score (8 domains) at Week 12</measure>
    <time_frame>Baseline and  Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The effect of GSK2586184 on health economics and general patient quality of life will be assessed by the SF-36 health survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Brief Fatigue Inventory (BFI) score</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>BFI is a fatigue assessment tool that asks patients to rate their current level of fatigue, usual fatigue and, worst level of fatigue in the last 24 hours, and how fatigue has interfered with general activity, mood, walking, work, relationships, and enjoyment of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Brief Pain Inventory (BPI) (short form) score</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>BPI allows subjects to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>GSK2586184 50 mg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the GSK2586184 50 mg Arm will receive twice daily dose of GSK2586184 50 mg 1 x 50 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586184 100 mg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the GSK2586184 100 mg Arm will receive twice daily dose of GSK2586184 100 mg (2 x 50 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586184 200 mg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586184 400 mg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo arm will receive twice daily dose of 2 matching placebo tablets orally up to 12 weeks; taken with food, immediately following a meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2586184 50 mg</intervention_name>
    <description>GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.</description>
    <arm_group_label>GSK2586184 50 mg Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2586184 100 mg</intervention_name>
    <description>GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.</description>
    <arm_group_label>GSK2586184 100 mg Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2586184 200 mg</intervention_name>
    <description>GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.</description>
    <arm_group_label>GSK2586184 200 mg Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2586184 400 mg</intervention_name>
    <description>GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.</description>
    <arm_group_label>GSK2586184 400 mg Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablet will be administered orally twice daily up to 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>GSK2586184 50 mg Arm</arm_group_label>
    <arm_group_label>GSK2586184 200 mg Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &amp; Gender: Male or female between 18 and 75 years of age inclusive

          -  SLE classification: a clinical diagnosis of SLE according to the American College of
             Rheumatology (ACR) classification criteria

          -  Severity of disease: clinically active SLE disease defined as a SELENA SLEDAI score
             ≥8 at screening

          -  Auto antibodies: serologically active having unequivocally positive anti-nuclear
             antibody (ANA) or anti-double stranded DNA (anti-dsDNA) antibody test results from 2
             independent time points

          -  Treatment for SLE:  patient stable on either no treatment or a stable dose of:
             corticosteroids (&lt;=15 mg/day prednisolone or equivalent) and /or hydroxychloroquine
             (&lt;=400 mg daily dose) Subjects receiving azathioprine (&lt;=2 mg/kg/day or &lt;=150 mg/day,
             whichever is greater) or mycophenolate mofetil (&lt;=1.5 g/day), or methotrexate (MTX)
             (&lt;=20 mg/week), either alone or in addition to steroids and / or hydroxychloroquine

          -  Prevention of Pregnancy:

        A female Subject is eligible to participate if she is not pregnant or nursing; is of
        non-childbearing potential. Females of child-bearing potential must agree to use one
        highly effective contraception method in addition to barrier protection OR two forms of
        highly effective contraception.

          -  Informed consent: Capable of giving written informed consent

        Exclusion Criteria:

          -  Kidney Disease: meeting any of  the following criteria:

        Proteinuria &gt; 0.5g/24 hour OR equivalent spot urine protein to creatinine ratio of
        0.5mg/mg; Serum creatinine &gt; 1.5 X upper limit of normal (ULN); active nephritis requiring
        acute therapy not permitted by protocol; required peritoneal dialysis or hemodialysis or
        high dose corticosteroid (&gt; 100 mg/day prednisone or equivalent) within 90 days prior to
        first dose; active renal disease shown on renal biopsy in the three months prior to
        screening.

          -  CNS Disease: active central nervous system (CNS) lupus (including seizures,
             psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis or CNS
             vasculitis) requiring therapeutic intervention within 60 days prior to first dose.

          -  Alcohol Abuse: Evidence or, in the opinion of the investigator, suspicion of alcohol
             consumption exceeding national guidelines and / or symptoms of alcohol dependency.

          -  Substance abuse: evidence of current recreational drug abuse or dependence.

          -  Hepatitis B: A positive pre-study Hepatitis B surface antigen or anti-Hepatitis B
             core antibody test at screening

          -  Hepatitis C: A positive Hepatitis C antibody at screening.

          -  HIV: A positive test for HIV antibody

          -  Previous Investigational Product Exposure:

        The subject has participated in a clinical trial and has received an investigational
        product within 30 days, 5 half-lives or twice the duration of the biological effect of the
        investigational product (whichever is longer) prior to the first dosing day in the current
        study; OR exposure to more than four new chemical entities within 12 months prior to the
        first dosing day.

          -  Previous and current medication: Use of prescription or non-prescription drugs,
             including: agents known to interact with GSK2586184, erythopoetic stimulation
             factors; vitamins, herbal and dietary supplements

          -  Prior biological therapies:  treatment with a biological therapy within the last 12
             months

          -  Transplantation: Have a history of a major organ transplant (e.g., heart, lung,
             kidney, liver) or hematopoietic stem cell/marrow transplant.

          -  Uncontrolled Other Diseases: Have clinical evidence of significant unstable or
             uncontrolled acute or chronic diseases not due to SLE  which, in the opinion of the
             investigator, could confound the results of the study or put the subject at undue
             risk.

          -  Surgery and Other Conditions: Have a planned surgical procedure or a history of any
             other medical disease laboratory abnormality, or condition  that, in the opinion of
             the investigator, makes the subject unsuitable for the study.

          -  Cancer: Have a history of malignant neoplasm within the last 5 years, except for
             adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ
             of the uterine cervix.-

          -  Infections:  have required management of acute or chronic infections as follows:
             currently on any suppressive therapy for a chronic infection (such as pneumocystis,
             cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria); OR
             hospitalisation for treatment of infection OR use of parenteral (IV or intramuscular)
             antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents)
             within 60 days prior to first dose.

          -  Mycobacterium Tuberculosis: Known latent or active infection with Mycobacterium
             Tuberculosis. Screening procedures consistent with local guidelines should be
             implemented.

          -  Haematology:  neutrophil count &lt;=1.5 X 10^9/L, Hb &lt;=10g/dL, lymphocyte count
             &lt;=350/mm^3 or 0.35 x 10^9/L and platelet count &lt;=100 X 10^9/L

          -  Serum immunoglobulin (Ig) levels:  IgG and/or IgM &lt;= the lower limit of normal (LLN)

          -  Liver function tests: Aspartate aminotransferase (AST) and alanine aminotransferase
             (ALT) &gt;=2x upper limit of normal (ULN); alkaline phosphatase and bilirubin &gt;1.5xULN
             (isolated bilirubin &gt;1.5ULN is acceptable if bilirubin is fractionated and direct
             bilirubin &lt;35%).

          -  Other laboratory abnormalities: Any Grade 3 or 4 haematology or clinical chemistry
             laboratory abnormality

          -  Drug sensitivity: History of sensitivity to any of the study medications, or
             components thereof or a history of drug or other allergy that, in the opinion of the
             investigator or GSK Medical Monitor, contraindicates their participation.

          -  Blood donation: Where participation in the study would result in donation of blood or
             blood products in excess of 500 mL within a 56 day period.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>J5402DIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>12850</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>11312</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pessac cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heraklion-Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Victoria</city>
        <state>Lima</state>
        <zip>Lima 13</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Borja</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surco</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-297</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-856</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>11172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parow</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pinelands, Cape Town</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>adaptive design</keyword>
  <keyword>clinical safety and efficacy</keyword>
  <keyword>pharmacodynamics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
